醫脈通(02192.HK)擬全球發售1.55億股 引入騰訊及富達國際等多家基石
格隆匯6月30日丨醫脈通(02192.HK)發佈公告，公司擬全球發售約1.55億股股份，其中香港發售股份1551萬股，國際發售股份約1.396億股，另有15%超額配股權；2021年6月30日至7月7日招股，預期定價日爲7月7日；發售價每股發售股份24.10-27.20港元，每手買賣單位500股，入場費約13737港元；高盛及海通國際爲聯席保薦人，預期股份將於2021年7月15日於聯交所主板掛牌上市。
根據弗若斯特沙利文報告，按截至2020年12月31日註冊醫師用戶數目計，集團是中國最大的在線專業醫師平臺。20多年來，集團致力以科技創新助力醫師作出更好的臨牀決策。集團自主開發的醫脈通平臺亦廣獲中國醫師認可，已成爲最受歡迎的專業醫療平臺，讓集團成爲中國製藥及醫療設備公司精準數字醫療營銷的首選平臺。根據弗若斯特沙利文報告，截至2020年12月31日，集團的醫脈通平臺可透過網站、桌面應用程序及移動應用程序登入，約有350萬註冊用戶，其中約240萬用戶爲執業醫師，佔截至同日中國所有執業醫師約58%。2020年第四季度，集團平臺的平均每月活躍用戶數超過100萬人。同一期間，註冊用戶每月在集團的平臺平均觀看文章和視頻超過134百萬次。集團平臺的文章和視頻包括(但不限於)臨牀指南、研究文獻、用藥參考、臨牀進展和定製內容。
集團已經與基石投資者訂立基石投資協議，基石投資者已同意按發售價認購以總金額2.20億美元(約17.0782億港元)發售股份數目。假設發售價爲25.65港元(即發售價範圍中間價)，基石投資者將認購的發售股份總數爲6657.95萬股。基石投資者包括FMR、富達國際 、騰訊控股全資附屬公司Tencent Mobility、GIC、Matthews Funds、Springhill及OrbiMed Funds 。
假設發售價爲每股股份25.65港元(即指示發售價範圍每股24.10至27.20港元的中間價)，且並無行使超額配股權，集團估計全球發售所得款項淨額約爲37.708億港元。其中，所得款項淨額所得款項淨額約40%擬用於在未來三至五年內擴展業務；約30%擬用於在未來三至五年內投資技術及提高研發能力；約20%擬用於有精心挑選戰略投資或收購機會；及所得款項淨額約10%擬用作一般補充營運資金及其他一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
